ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1922

Analysis of Characteristics and Risk Factors of Sepsis in Patients with Lupus Nephritis

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Xu, Zhenjian, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
  • Liang, Meisheng, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
  • Xu, Anping, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
Background

Patients with lupus nephritis are at high risk of infection due to intrinsic immune dysregulation and treatment with glucocorticoids and immunosuppressants. Infection is a common complication in patients with lupus nephritis and is a major determinant of in-hospital mortality. Sepsis are the most frequent causes of infection-related mortality. In this research, we study the clinical characteristics and related risk factors of sepsis in patients with lupus nephritis according to a retrospective analysis.

Methods

A retrospective study was carried out for 322 hospitalized patients with lupus nephritis in Sun Yat-Sen Memorial Hospital from 2010 to 2019. The infected group consisted of 140 patients (The infected patients were subdivided into septic group and non-septic group according the sepsis criteria) while the non-infected group consisted of 182 patients without infection. Baseline data including sex, age, disease duration, hospitalization duration, associated organ involvement, use of glucocorticoid and immunosuppressants.

Results

Compared to the non-infected group, longer hospitalization duration(14 vs. 9d,P<0.05), pulsed methylprednisolone treatment within 1 month(10.7% vs. 1.6%,P<0.05), cyclophosphamide(22.9% vs. 14.3%,P<0.05), and calcineurin inhibitors(18.6% vs. 10.4%,P<0.05), and higher dose of oral corticosteroid(15 vs. 10mg,P<0.05)can be seen in the infected group (P<0.05). Compared to the non-septic group, higher proportion of male(21.2% vs. 8.0%,P<0.05), higher SELDAI score(9.0 vs. 6.0,P<0.05), higher proportion of pulsed methylprednisolone treatment within 1 month(13.5% vs. 10.7%,P<0.05)and higher dose of oral corticosteroid(20.0 vs. 15.0mg,P<0.05)can be seen in the septic group (P<0.05). About the laboratory results, lower level of platelet(129.0 vs. 194.5×109/L,P<0.05)and lymphocyte(0.6 vs. 0.9×109/L,P<0.05), while higher level of serum creatine(134.0 vs. 88.0μmol/L,P<0.05), C reactive protein(43.8 vs. 12.3mg/L,P<0.05)and erythrocyte sedimentation rate(60.0 vs. 45.5mm/h,P<0.05) can be seen in the septic group. Multivariate Logistic regression analysis revealed that male and pulse methylprednisolone treatment within 1 month were independent risk factors of sepsis in patients with lupus nephritis (P<0.05).

Conclusion

Male and pulse methylprednisolone treatment within 1 month were independently associated with sepsis in patients with lupus nephritis.